Nipah Virus Therapeutics: A Systematic Review to Support Prioritisation for Clinical Trials
Authors:
- Xin Hui S ChanXCXin Hui S Chan
- Ilsa L HaeuslerIHIlsa L Haeusler
- Bennett J K ChoyBCBennett J K Choy
- Junko TakataJTJunko Takata
- Tara P HurstTHTara P Hurst
- Luke M JonesLJLuke M Jones
- Shanghavie LoganathanSLShanghavie Loganathan
- Elinor HarrissEHElinor Harriss
- Jake DunningJDJake Dunning
- Joel TarningJTJoel Tarning
- Miles W CarrollMCMiles W Carroll
Preprint
Abstract
Nipah virus disease is a bat-borne zoonosis with person-to-person transmission, a case fatality rate of 38-75%, and recognised pandemic potential. The first reported outbreak occurred in Malaysia and Singapore in 1998, since followed by multiple outbreaks in Bangladesh and India. No therapeutics or vaccines have been licensed to date, and only few candidates are in development. This systematic review aimed to assess the evidence for the safety and efficacy of therapeutic options (monoclonal antibodies and small molecules) for Nipah virus and other henipaviral diseases in order to support candidate prioritisation for further evaluation in clinical trials. At present, there is sufficient evidence to trial only m102.4 and remdesivir (singly and/or in combination) for prophylaxis and early treatment of Nipah virus disease. In addition to well-designed clinical efficacy trials, in vivo pharmacokinetic-pharmacodynamic studies to optimise selection and dosing of therapeutic candidates in animal challenge and natural human infection are needed. Research in context: Evidence before this study: Nipah virus infection is a bat-borne zoonosis with person-to-person transmission, a case fatality rate of 38-75%, and recognised pandemic potential. No therapeutics or vaccines have been licensed to date, and only few candidates are in development. We conducted this systematic review to assess the evidence for the safety and efficacy of therapeutic options (monoclonal antibodies and small molecules) for Nipah virus and other henipaviral diseases to support candidate prioritisation for further evaluation in clinical trials. We searched bibliographic databases for journal articles, conference abstracts, and patents: PubMed, Ovid Embase, Ovid CAB Abstracts, Ovid Global Health, Scopus, Web of Science (all databases), and the WHO Global Index Medicus. “Henipavirus” or “Nipah” or “Hendra” along with “therapeutics” or “monoclonal” were the title, abstract, and subject heading keywords, with synonyms and variant spellings as additional search terms. We searched trial registries for clinical trials of Henipavirus, Nipah virus, and Hendra virus at all stages of recruitment: Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform. We searched the Trip database and WHO website for guidelines and reports. All searches were conducted on 30 May 2022. We did not apply language or publication date limits. Studies were included if they contained primary data on the safety and/or efficacy of monoclonal antibodies ( in vivo) or small molecules ( in vivo or in vitro ) for the treatment and/or prophylaxis of Nipah, Hendra, and related Henipaviridae . Almost all had critical or high risk of bias. Added value of this study: This is the most detailed systematic review and analysis of the Nipah virus therapeutics landscape to date, including all available in vivo and related in vitro data on the safety, efficacy, and pharmaco-kinetics of monoclonal antibodies and small molecules with the specific aim of supporting prioritisation for clinical trials. We also present a roadmap for how in vivo development of Nipah therapeutics could be strengthened to achieve greater equity, efficiency, and effectiveness. Implications of the available evidence: At present, there is sufficient evidence to trial only m102.4 and remdesivir for prophylaxis and early treatment of Nipah virus infection. Well-designed clinical efficacy trials as well as in vivo pharmacokinetic-pharmacodynamic studies to optimise selection and dosing of therapeutic candidates in animal challenge and natural human infection are needed.Keywords
This publication has 84 references indexed in Scilit:
- Nonhuman Primate Models for Nipah and Hendra Virus Countermeasure Evaluation2023
- Ferret Models for Henipavirus Infection2023
- Syrian Golden Hamster Model for Nipah Virus Infection2023
- Population pharmacokinetics of favipiravir in patients with COVID‐19CPT: Pharmacometrics & Systems Pharmacology, 2021
- Henipaviruses2016
- Long‐term neurological and functional outcome in Nipah virus infectionAnnals of Neurology, 2007
- RNA synthesis during infection by Hendra virus: an examination by quantitative real-time PCR of RNA accumulation, the effect of ribavirin and the attenuation of transcriptionArchives of Virology, 2004
- Relapsed and late‐onset Nipah encephalitisAnnals of Neurology, 2002
- Treatment of acute Nipah encephalitis with ribavirinAnnals of Neurology, 2001
- The neurological manifestations of Nipah virus encephalitis, a novel paramyxovirusAnnals of Neurology, 1999